📊 DNABW Key Takeaways
Is Ginkgo Bioworks Holdings, Inc. (DNABW) a Good Investment?
Ginkgo Bioworks is a pre-commercial biotech company burning substantial cash with significant losses and negative margins across all profitability measures. While the company maintains adequate liquidity with $167.2M in cash and a 4.92x current ratio, the severe operating losses (-$315.3M), deteriorating revenue (-25.1% YoY), and substantial negative free cash flow (-$178.7M) indicate the business model has not yet achieved commercial viability. At the current cash burn rate, the company has limited runway without significant operational improvements or additional capital raises, presenting substantial execution risk.
Ginkgo Bioworks shows very weak fundamentals: revenue is declining sharply, operating and net margins are deeply negative, and free cash flow remains heavily negative relative to sales. The balance sheet still has meaningful liquidity and no material leverage, but the current cash burn and lack of profitable growth materially weaken financial quality unless losses narrow substantially.
Why Buy Ginkgo Bioworks Holdings, Inc. Stock? DNABW Key Strengths
- Strong liquidity position with $167.2M cash and 4.92x current ratio provides runway for operations
- Minimal debt burden with 0.00x debt-to-equity ratio reduces financial leverage risk
- Modest insider activity suggests some level of confidence from company leadership
- Strong near-term liquidity with a 4.92x current and quick ratio
- No meaningful balance-sheet leverage, reducing insolvency risk from debt
- Large asset base and positive equity provide some financial flexibility
DNABW Stock Risks: Ginkgo Bioworks Holdings, Inc. Investment Risks
- Severe operating losses of -$315.3M with -185.3% operating margin indicate business is far from profitability
- Revenue declined 25.1% year-over-year despite being pre-commercial, suggesting market execution challenges
- Negative free cash flow of -$178.7M annually will deplete cash reserves within approximately 12-15 months without improvement
- Diluted EPS of -$5.64 and negative ROE/ROA indicate value destruction for shareholders
- No gross profit reporting suggests potential product costing or revenue recognition issues
- Revenue declined 25.1% YoY, indicating weak growth quality and potential demand or execution issues
- Operating margin of -185.3% and net margin of -183.8% show an unsustainable cost structure
- Free cash flow of -$178.72M and operating cash flow of -$171.06M imply continued cash burn
Key Metrics to Watch
- Revenue growth trajectory and return to positive growth rate
- Operating cash flow and free cash flow to assess path to cash flow breakeven
- Cash and equivalents levels and monthly burn rate relative to runway
- Gross margin when reportable to understand unit economics and product viability
- Operating expense reduction initiatives to achieve operating profitability timeline
- Revenue growth stabilization or reacceleration
- Operating cash flow and free cash flow burn reduction
Ginkgo Bioworks Holdings, Inc. (DNABW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.92x current ratio provides a solid financial cushion.
DNABW Profit Margin, ROE & Profitability Analysis
DNABW vs Healthcare Sector: How Ginkgo Bioworks Holdings, Inc. Compares
How Ginkgo Bioworks Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ginkgo Bioworks Holdings, Inc. Stock Overvalued? DNABW Valuation Analysis 2026
Based on fundamental analysis, Ginkgo Bioworks Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ginkgo Bioworks Holdings, Inc. Balance Sheet: DNABW Debt, Cash & Liquidity
DNABW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ginkgo Bioworks Holdings, Inc.'s revenue has declined by 20% over the 5-year period, indicating business contraction. The most recent EPS of $-18.37 indicates the company is currently unprofitable.
DNABW Revenue Growth, EPS Growth & YoY Performance
DNABW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $38.8M | -$56.4M | $-1.08 |
| Q2 2025 | $49.6M | N/A | $-1.10 |
| Q1 2025 | $37.9M | N/A | $-1.68 |
| Q3 2024 | $55.4M | -$56.4M | $-1.08 |
| Q2 2024 | $56.2M | -$173.3M | $-0.09 |
| Q1 2024 | $37.9M | N/A | $-0.08 |
| Q3 2023 | $55.4M | -$302.9M | $-0.16 |
| Q2 2023 | $80.6M | -$173.3M | $-0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ginkgo Bioworks Holdings, Inc. Dividends, Buybacks & Capital Allocation
DNABW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ginkgo Bioworks Holdings, Inc. (CIK: 0001830214)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 14, 2026 | 4 | xslF345X06/wk-form4_1776200454.xml | View → |
| Apr 13, 2026 | 4 | xslF345X06/wk-form4_1776114037.xml | View → |
| Apr 13, 2026 | 4 | xslF345X06/wk-form4_1776114009.xml | View → |
| Apr 10, 2026 | 4 | xslF345X06/wk-form4_1775854931.xml | View → |
| Apr 10, 2026 | 4 | xslF345X06/wk-form4_1775854911.xml | View → |
❓ Frequently Asked Questions about DNABW
What is the AI rating for DNABW?
Ginkgo Bioworks Holdings, Inc. (DNABW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DNABW's key strengths?
Claude: Strong liquidity position with $167.2M cash and 4.92x current ratio provides runway for operations. Minimal debt burden with 0.00x debt-to-equity ratio reduces financial leverage risk. ChatGPT: Strong near-term liquidity with a 4.92x current and quick ratio. No meaningful balance-sheet leverage, reducing insolvency risk from debt.
What are the risks of investing in DNABW?
Claude: Severe operating losses of -$315.3M with -185.3% operating margin indicate business is far from profitability. Revenue declined 25.1% year-over-year despite being pre-commercial, suggesting market execution challenges. ChatGPT: Revenue declined 25.1% YoY, indicating weak growth quality and potential demand or execution issues. Operating margin of -185.3% and net margin of -183.8% show an unsustainable cost structure.
What is DNABW's revenue and growth?
Ginkgo Bioworks Holdings, Inc. reported revenue of $170.2M.
Does DNABW pay dividends?
Ginkgo Bioworks Holdings, Inc. does not currently pay dividends.
Where can I find DNABW SEC filings?
Official SEC filings for Ginkgo Bioworks Holdings, Inc. (CIK: 0001830214) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DNABW's EPS?
Ginkgo Bioworks Holdings, Inc. has a diluted EPS of $-5.64.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DNABW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ginkgo Bioworks Holdings, Inc. has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DNABW stock overvalued or undervalued?
Valuation metrics for DNABW: ROE of -61.5% (sector avg: 15%), net margin of -183.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DNABW stock in 2026?
Our dual AI analysis gives Ginkgo Bioworks Holdings, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DNABW's free cash flow?
Ginkgo Bioworks Holdings, Inc.'s operating cash flow is $-171.1M, with capital expenditures of $7.7M. FCF margin is -105.0%.
How does DNABW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -183.8% (avg: 12%), ROE -61.5% (avg: 15%), current ratio 4.92 (avg: 2).